Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07518654Phase 1Not Yet Recruiting

Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

Role: collaborator

NCT04990323Phase 1Completed

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Role: lead

NCT04103879Phase 2Completed

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

Role: lead

NCT03441958Phase 1Completed

ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Role: collaborator

NCT03913026Phase 2Active Not Recruiting

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

Role: collaborator

NCT04594031Phase 1Withdrawn

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

Role: lead

All 6 trials loaded